deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02488044

A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102

Sponsor: Aeglea Biotherapeutics

Conditions Arginase I Deficiency Hyperargininemia
Interventions AEB1102
Updated 13 times since 2017 Last updated: Jun 11, 2019 Started: Jun 30, 2016 Primary completion: Feb 28, 2019 Completion: Feb 28, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Arginase I Deficiency and Hyperargininemia and is currently completed. Aeglea Biotherapeutics leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jul 2019 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Apr 2019 — Jul 2019 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 8 earlier versions

  1. Jan 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  4. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aeglea Biotherapeutics
Data source: Aeglea Biotherapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations